Product Description
Plecanatide is used in adults to treat chronic idiopathic constipation (CIC; difficult or infrequent passage of stools that lasts for 3 months or longer and is not caused by a disease or a medication) and irritable bowel syndrome with constipation (IBS-C; a condition that causes stomach pain or cramps, bloating, and constipation.) Plecanatide is in a class of medications called guanylate cyclase-C agonists. It works by increasing the movement of food and waste through the stomach and intestines. (Sourced from: https://medlineplus.gov/druginfo/meds/a617020.html)
Mechanisms of Action: GUC Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | United States
Approved Indications: None
Known Adverse Events: None
Company: Bausch Health Americas
Company Location: QUEBEC A8 H7L 4A8
Company CEO: Thomas J. Appio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Constipation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NC011901 | P3 |
Completed |
Constipation |
2023-10-12 |
53% |
2024-07-12 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/09/2024 |
News Article |
Metabolomics Market Surges to USD 7.22 Billion by 2031, Propelled by 13.13% CAGR - Verified Market Research® |
|
06/28/2024 |
News Article |
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines |
|
10/10/2023 |
News Article |
Oral Proteins and Peptides Market Size, Share and Forecast 2031 |
|
10/09/2023 |
News Article |
Myopia and Presbyopia Market Top Leading Players with Strategies and Forecast 2031 |